Notable Labs(NTBL) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____. Commission file number 001-36581 (Mark One) Vascular Biogenics Ltd. (Exact name of registrant as specified in its charter) Israel Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8 HaSatat St. Modi'in, Israel 7178106 (Address o ...